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What is already known on this topic?
 Ź Late- onset infection (LOI) in preterm infants is 
associated with a higher risk of mortality and 
long- term neurodevelopmental impairment.
 Ź Antibiotic treatment is onerous, expensive and 
risky.
 Ź Studies in children and adults suggest that 
antibiotic- impregnated peripherally inserted 
central catheters (PICCs) are effective and cost- 
effective in reducing bloodstream infections.
What this study adds?
 Ź The study presents a new decision analytic 
model which can be used to evaluate 
alternative strategies to prevent LOI.
 Ź Antibiotic- impregnated PICCs are not cost- 
effective, when compared with standard 
PICCs, in a group of infants born ≤32 weeks 
gestational age.
 Ź Strategies preventing LOI have a great potential 
to be cost- effective, even when minimally 
effective.
ABSTRACT
Objective Developing a model to analyse the cost- 
effectiveness of interventions preventing late- onset 
infection (LOI) in preterm infants and applying it to the 
evaluation of anti- microbial impregnated peripherally 
inserted central catheters (AM- PICCs) compared with 
standard PICCs (S- PICCs).
Design Model- based cost- effectiveness analysis, using 
data from the Preventing infection using Antimicrobial 
Impregnated Long Lines (PREVAIL) randomised controlled 
trial linked to routine healthcare data, supplemented 
with published literature. The model assumes that LOI 
increases the risk of neurodevelopmental impairment 
(NDI).
Setting Neonatal intensive care units in the UK 
National Health Service (NHS).
Patients Infants born ≤32 weeks gestational age, 
requiring a 1 French gauge PICC.
Interventions AM- PICC and S- PICC.
Main outcome measures Life expectancy, quality- 
adjusted life years (QALYs) and healthcare costs over the 
infants’ expected lifetime.
Results Severe NDI reduces life expectancy by 14.79 
(95% CI 4.43 to 26.68; undiscounted) years, 10.63 
(95% CI 7.74 to 14.02; discounted) QALYs and costs 
£19 057 (95% CI £14 197; £24697; discounted) to the 
NHS. If LOI causes NDI, the maximum acquisition price 
of an intervention reducing LOI risk by 5% is £120. 
AM- PICCs increase costs (£54.85 (95% CI £25.95 to 
£89.12)) but have negligible impact on health outcomes 
(−0.01 (95% CI −0.09 to 0.04) QALYs), compared 
with S- PICCs. The NHS can invest up to £2.4 million in 
research to conirm that AM- PICCs are not cost- effective.
Conclusions The model quantiies health losses and 
additional healthcare costs caused by NDI and LOI during 
neonatal care. Given these consequences, interventions 
preventing LOI, even by a small extent, can be cost- 
effective. AM- PICCs, being less effective and more costly 
than S- PICC, are not likely to be cost- effective.
Trial registration number NCT03260517.
INTRODUCTION
Preterm infants hospitalised in neonatal inten-
sive care units (NICUs) often require a periph-
erally inserted central catheter (PICC) to receive 
medicines, fluids and parenteral nutrition.1 PICCs 
provide a conduit for microorganisms to enter 
the bloodstream and a site where microorganisms 
can proliferate, increasing the risk of late- onset 
infection (LOI). LOI has been linked to higher 
risk of death and permanent neurodevelopmental 
impairment (NDI).2 3 Furthermore, treating LOI 
with antibiotics is harmful to the developing gut 
microbiome,4 potentially leading to serious condi-
tions such as necrotising enterocolitis.57
Antimicrobial impregnated PICCs (AM- PICCs) 
have been shown to prevent LOI in adults and 
children but evidence is sparse in preterm infants.8 
To address this evidence gap, the PREVAIL trial 
(NIHR HTA 12/167/02) investigated the safety, 
effectiveness and cost- effectiveness of AM- PICCs 
versus standard non- impregnated PICCs (S- PICCs) 
in reducing LOI in prematurity.9
This study reports the cost- effectiveness model 
to establish the long- term value of preventing LOI 
in preterm infants hospitalised in NICUs, and its 
application to estimate the cost- effectiveness of 
AM- PICCs versus S- PICCs. The model uses data 
from PREVAIL, linked to hospital use collected 
from the UK National Neonatal Research Database 
(NNRD), Hospital Episode Statistics (HES) and 
Paediatric Intensive Care Network (PICANet) to 
estimate costs, alongside evidence from the external 
literature on the long- term health and economic 
consequences of LOI.
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Figure 1 Model diagram. GA, gestational age; NDI, neurodevelopmental impairment; PICC, peripherally inserted central catheter.
METHODS
A new decision analytic model was developed to simulate the 
lifetime costs, life expectancy and quality- adjusted life years 
(QALYs10RILQIDQWVERUQZHHNVJHVWDWLRQDODJH*$ZKR
UHTXLUHGD3,&&GXULQJWKHLU1,&8VWD\*LYHQWKHLPSDFWRI*$
RQKHDOWKRXWFRPHVUHVXOWVDUHSUHVHQWHGIRUWZRVXEJURXSV*$
²ZHHNVDQG*$²ZHHNV&RVWVDUHH[SUHVVHGLQ8.
pound sterling at a 2016 price base, from the perspective of the 
UK NHS. Future costs and QALYs are discounted at 3.5% per 
annum.11 The model was developed using Microsoft Excel.
Model structure
The model structure is represented in figure 1. Infants enter the 
model at the time of PICC insertion and are at risk of LOI. LOI 
increases the risk of death and NDI (but not its severity). At 2 
years of age, children are assessed for the presence and severity 
of NDI. From age 2 onwards, the model follows the same struc-
ture as the model by Mangham et al, which estimated the costs 
of prematurity.12 Children transition between NDI states or die. 
The transitions represent improvement or deterioration in NDI 
status, as well as inaccuracies in the assessment, which might 
appear over time. After reaching age 8, children remain at risk of 
death but their NDI level is assumed to remain stable.
Model parameterisation
Model parameters are presented in table 1.
LOI corresponds to clinically serious bloodstream infection 
LQ WKH35(9$,/WULDO VXEJURXSZLWK*$ZHHNVDSUDJ-
matic randomised controlled trial performed across 18 NICUs in 
England. Infants requiring a narrow (1 French) gauge PICC were 
considered eligible and once enrolled in the trial were allocated 
1:1 to receive either a PICC impregnated with miconazole and 
rifampicin (AM- PICC) or an S- PICC. Clinically serious blood-
stream infection, defined as positive blood/cerebrospinal fluid 
culture and >72 hours treatment with intravenous antibiotic, or 
death during treatment, was thought to be closer to the defini-
tion of LOI in the literature than PREVAILs primary outcome of 
any positive blood/cerebrospinal fluid culture.9
The probability of death at 6 months was informed by an 
observational study covering all NICUs in England, for a total of 
7369 hospitalised infants in 201413; details in online supplemen-
tary material 1. The probability of death between 6 months and 
2 years of age if infants had received S- PICC was sourced from 
Mangham et al,12 and based on data from the 9192 Victorian 
Infant Collaborative Study Cohort.14 The probability of death 
from age 2 was obtained from the UK lifetables 201315,15 to 
which the excess risk due to NDI was added16; see online supple-
mentary material 2.
The probability of NDI, its severity and the probability of 
progression between NDI levels over time was also obtained 
from Mangham et al12; for details see online supplemen-
tary material 3. Mangham et al12 defined NDI as a composite 
outcome encompassing visual, hearing, mobility and cognitive 
impairment.14 Each item is assigned a level ranging from no to 
severe disability following standardised paediatric tests, with the 
most severe level of impairment recorded identifying the overall 
NDI for the infant.14 17 18
A pearl growing review and meta- analysis was conducted to 
estimate the effect of LOI on death and NDI19; details in online 
supplementary material 4. The search started from Stoll et al,2 
a US observational study linking LOI to death and NDI. Studies 
were selected if their definition of LOI was consistent with the 
PREVAIL trial, and if their definition of NDI was consistent with 
Mangham et al.12 Three systematic reviews were identified,2023 
from which Schlabpach et al24 and Bassler et al25 were selected. 
Stoll et al2 and Schlabpach et al24 were meta- analysed to inform 
the added risk of developing NDI at 2 years of age given LOI 
(1.51, 95% CI 1.33 to 1.70), while Schlapbach et al24 and Bassler 
et al25 were meta- analysed to inform the added risk of death 
between 6 months and 2 years of age, given LOI (2.74, 95% CI 
1.43 to 5.24).
Costs
The cost of S- PICC and AM- PICC was provided by the manufac-
turer (personal communication).
Costs between PICC insertion and 6 months were calculated 
using routine healthcare data of the infants enrolled in the 
PREVAIL trial: NNRD for the NICU stay, PICANet for stays in 
the paediatric intensive care unit, HES inpatient, HES outpatient 
and accident and emergency. Details of all data items are search-
able at NHS.26 Hospital care was costed using NHS Reference 
Cost 15/16.27)RUWKHEDVHFDVHFRVWVGHSHQGRQO\RQ*$)RU
details, see online supplementary material 5.
Costs between 6 months and 2 years of age were calculated 
from the use of hospital care by preterm infants derived from 
HES inpatient, A&E and outpatient data, costed with NHS 
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Table 1 Model parameters
Parameter Value GA 23–27 weeks (95% CI; 
distribution)
Value GA 28–32 weeks (95% CI; 
distribution)
Source
Effect of AM- PICC on the probability of LOI
Relative risk of AM- PICC vs S- PICC 1.06 (0.70 to 1.60; lognormal) PREVAIL trial (subgroup of infants born ≤32 weeks GA).
Effect of LOI on NDI and death
Relative risk of the effect of LOI on 
death at 6 months
1 (ixed) Assumed that LOI has no effect on death at 6 months 
in the base case.
OR for the effect of LOI on NDI at 
2 years of age
1.51 (1.33 to 1.70; lognormal) Meta- analysis of Stoll et al2 and Schlapbach et al.24
OR for the effect of LOI on death at 
2 years of age
2.74 (1.43 to 5.24; lognormal) Meta- analysis of Schlapbach et al24 and Bassler et al.25
Probabilities using S- PICC
Probability of LOI 0.14 (0.09 to 0.20; beta) 0.04 (0.02 to 0.08; beta) PREVAIL trial (subgroup of infants born ≤32 weeks GA).
Probability of death between PICC 
insertion and 6 months
0.20 (0.16 to 0.23; beta) 0.03 (0.03 to 0.04; beta) Santhakumaran et al.13
Probability of death between 
6 months and 2 years
0.02 (0.01 to 0.03; beta) 0.01 (0.00 to 0.02; beta) Mangham et al.12 Estimates refer to a population of 
infants with different LOI status and applied to the non- 
infected infants (see online supplementary material 1).
Probability of developing NDI 0.45 (0.42 to 0.49; dirichlet) 0.26 (0.25 to 0.28; dirichlet) Mangham et al.12 Estimates refer to a population of 
infants with different LOI status and applied to the 
non- infected infants.
Distribution by NDI levels, given that NDI occurred
Mild NDI 0.54 (0.51 to 0.58; dirichlet) 0.73 (0.70 to 0.76; dirichlet) Mangham et al12 assumed to be similar for both sepsis 
and non- sepsis groups. Severe NDI calculated as the 
complement.
Moderate NDI 0.29 (0.28 to 0.30; dirichlet) 0.16 (0.15 to 0.17; dirichlet)
Health- related quality of life (to calculate QALYs)
No NDI 0.96 (0.94 to 0.97; beta) Petrou et al29
Mild NDI decrement 0.18 (0.14 to 0.31; gamma) Petrou et al29
Moderate NDI decrement 0.30 (0.24 to 0.46; gamma) Petrou et al29
Severe NDI decrement 0.56 (0.44 to 0.77; gamma) Petrou et al29
Costs
Difference in cost between PICCs 
(AM- PICC vs S- PICC)
£53.70 Personal communication from the manufacturer
Healthcare costs between PICC 
insertion and 6 months
£105 873.47 (101 444.99 to 110 495.27; 
gamma)
£62 255.37 (54 711.87 to 70 838.93; gamma) PREVAIL trial and linked datasets (NNRD, PICANet, 
HES).
Healthcare costs between 6 months 
and 2 years
£5989.17 (5989.14 to 5994.98) £3026.17 (3026.43 to 3028.73) NHS Reference Cost 15/1627 derived from HES inpatient, 
A&E and outpatient data.
Annual costs between age 2 and 10 years
No NDI £388 (£285 to £509; gamma) Petrou et al28 ; inlated to 2016
Mild NDI £753 (£584 to £946; gamma) Petrou et al28; inlated to 2016
Moderate NDI £814 (£560 to £1063; gamma) Petrou et al28; inlated to 2016
Severe NDI £1487 (£1096 to £1943; gamma) Petrou et al28; inlated to 2016
Annual costs after age 11 years
No NDI £686 (£440 to £993; gamma) Petrou et al29: inlated to 2016
Mild NDI £987 (£782 to £1222; gamma) Petrou et al29 ; inlated to 2016
Moderate NDI £1252 (£933 to 1624; gamma) Petrou et al29 ; inlated to 2016
Severe NDI £1976 (£1411 to £2648; gamma) Petrou et al29 ; inlated to 2016
GA, gestational age; HES, Hospital Episode Statistics; LOI, late- onset infection; NDI, neurodevelopmental impairment; NHS, National Health Service; NNRD, National Neonatal Research Database; 
PICANet, Paediatric Intensive Care Network; PICC, peripherally inserted central catheter; QALY, quality- adjusted life year.
Reference Costs 15/16.27 For details, see online supplementary 
material 6.
Annual costs by NDI level between 2 and 10 years of age 
were sourced from Mangham et al,12 which reports the results 
from the EPICure cohort at 6 years of age.28 The annual costs by 
1',OHYHO\HDUVRIDJHUHODWHGWRWKHVDPH(3,&XUHFRKRUW
obtained from Petrou et al.29 Costs from age 2 refer to any 
healthcare costs, both related and unrelated to NDI
Health-related quality of life
Health- related quality of life by NDI level was obtained from 
Petrou et al,29 which collected Health Utilities Index (HUI) 
Mark 3 at 11 years of age from parents of infants in the EPICure 
cohort. The HUI scores are applied throughout lifetime, and 
no additional decrement has been added to consider addi-
tional comorbidities due to, for example, age, given the lack of 
published estimates for people with NDI.
Analytical methods
Simulation methods were used to generate mean costs, life years 
and QALYs.30 The model estimated outcomes and costs given 
different levels of NDI at age 2, conditional on whether LOI 
occurred during the NICU stay, and by PICC type. The utility of 
the model in establishing which intervention is cost- effective was 
illustrated by the comparison between AM- PICC and S- PICC. 
The cost- effective intervention is the one which achieves the 
most health benefits given its costs and the cost- effectiveness 
threshold of £20 000/QALY,11 a benchmark of the maximum 
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Figure 2 Costs and health outcomes by NDI levels between age 2 and 
the infants’ expected lifetime. The graph shows NHS costs and health 
outcomes results obtained by running the long- term component of the 
model for each NDI level assuming that all infants in the cohort were 
assessed with the same level of impairment at two years of age. NDI, 
neurodevelopmental impairment; NHS, National Health Service; QALYs, 
quality- adjusted life years.
Figure 3 Maximum price by effectiveness level for a new hypothetical 
intervention. The graph represents, for each level of effectiveness, 
represented by the relative risk of LOI, the maximum price that could 
would still make such a new hypothetical intervention cost- effective, 
at a cost- effectiveness threshold of £20 000/QALY. GA, gestational age; 
QALY, quality- adjusted life year.
Table 2 Cost- effectiveness results
Cost- effectiveness 
results
Gestational age (weeks)
23–27 28–32
AM- PICC
Total costs (95% CI) £1 27 183 (120 983 to 133 919) £83 588 (77048 to 90 839)
Total QALYs (95% CI) 16.48 (15.41 to 17.59) 21.46 (20.67 to 22.17)
S- PICC
Total costs (95% CI) £1 27 128 (120 936 to 133 866) £83 533 (76 994 to 90 784)
Total QALYs (95% CI) 16.49 (15.44 to 17.60) 21.46 (20.67 to 22.17)
AM- PICC vs S- PICC
Cost difference (95% CI) £55 (26 to 89) £55 (48 to 64)
QALY difference (95% CI) −0.01 (−0.09 to 0.04) 0.00 (−0.01 to 0.01)
Incremental net health 
beneit at £20 000/QALY
−0.01 (−0.09 to 0.04) −0.01 (−0.02 to 0.00)
AM- PICC, antimicrobial impregnated PICC; PICC, peripherally inserted central catheter; QALY, 
quality- adjusted life year; S- PICC, standard PICC.
acceptable added cost per QALY gained commonly used for the 
UK NHS.11 The robustness of the results was assessed by varying 
the parameter values over the 95% CI and with scenario anal-
ysis. For details, see online supplementary material 8. The model 
was validated using the Advishe checklist,31 see online supple-
mentary material 9.
Exploring the value of further research
The model can calculate the health benefits of knowing which is 
the cost- effective intervention with absolute certainty (ie, with 
perfect information), the expected value of perfect information 
(EVPI).32 Using the cost- effectiveness threshold as the monetary 
value of 1 QALY, the health benefits can be converted to mone-
tary units. This represents the most that the UK NHS should 
invest in future research to inform a policy decision. The EVPI 
was calculated considering the uncertainty around all parame-
ters informing the model and for each individual parameter. It 
is presented for the preterm infant population in England over 
10 years, assuming that this is the population who would benefit 
from any future research. The calculations were conducted using 
the online SAVI simulator.33
RESULTS
Long-term value of preventing NDI
Figure 2 shows the outcomes by NDI level over the infants 
expected lifetime. The model predicts that, as the NDI level 
worsens, life expectancy and QALYs reduce, while costs increase. 
The long- term value of preventing NDI can be computed as the 
difference between the predicted QALYs and costs with and 
without impairment. As an example, the difference in costs and 
health outcomes between mild and no NDI is £3690 lower costs 
and 2.16 additional QALYs. If a QALY is valued at £20 00011 
avoiding mild NDI in one child warrants up to £46 890 (2.16 
QALYs×£20 000+£3690) in investment by the NHS.
Long-term value of preventing LOI
Figure 3 shows the relationship between the maximum acquisi-
tion price of interventions to prevent LOI and their effectiveness, 
assuming that 1 QALY is valued at £20 000.11 For instance, at 
*$²ZHHNVIRUHYHU\UHGXFWLRQLQUHODWLYHULVNRI/2,
cases (eg, from 0.95 to 0.90), the maximum price increases by 
%HFDXVHWKHULVNRI/2,LVORZHULQLQIDQWVZLWKROGHU*$V
(2832 weeks), the maximum acquisition price increases only 
by £20. A new hypothetical intervention reducing 20% of LOI 
(relative risk 0.8) could cost up to £479 and £79 and still be cost- 
effective in the subgroups of infants born at 2327 and 2832 
ZHHNV*$UHVSHFWLYHO\
Cost-effectiveness of an intervention to prevent LOI: AM-PICC 
versus S-PICC
The model can be used to analyse the cost- effectiveness of any 
intervention to prevent LOI in preterm infants during their stay 
in the NICU. To illustrate, table 2 shows the results of the cost- 
effectiveness analysis comparing AM- PICC with S- PICC. As 
expected given the results of the PREVAIL trial, AM- PICC is not 
cost- effective.
Sensitivity analysis
The results were robust to all sensitivity analyses and scenarios 
apart from varying the effect of AM- PICC in preventing LOI, 
and, to a smaller extent, the effect of LOI on the risk of death. 
For details, see online supplementary material 8.
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Value of further research
For the population of preterm babies, over a period of 10 years, 
the EVPI was £2.4 million. The model input driving the EVPI is 
the relative risk of LOI. This means that, if the UK NHS were 
to invest in more research to make sure that S- PICCs are the 
best policy, this research should be on another trial on the effec-
tiveness of S- PICCs versus AM- PICCs. Depending on the cost 
and the design of a new trial, and given that such a trial would 
not determine the relative risk with absolute certainty, further 
research on the comparison of AM- PICC with S- PICC may not 
be good value for money.
DISCUSSION
Summary of findings
A new decision analytic model was developed to predict the 
quality- adjusted life expectancy and lifetime NHS costs of 
infants using AM- PICC or S- PICC. Based on existing literature,2 
the model assumes that LOI negatively affects health outcomes. 
Under this assumption, a strategy to prevent LOI is valuable as it 
can lead to an increase in life expectancy, health- related quality 
of life and a reduction in costs. AM- PICCs, however, being more 
costly and with no evidence of benefits over S- PICC, are not 
cost- effective. Whether more research on the effectiveness of 
AM- PICC versus S- PICC is cost- effective depends on the cost 
and the design of future trials.
Strengths
This study represents the first attempt at estimating the cost- 
effectiveness of AM- PICCs in the NICU setting. Available 
studies on impregnated PICCs considered older populations and 
different antimicrobials agents, precluding meaningful compar-
isons.3437 The model synthesises relevant information on the 
costs and consequences of LOI. It is flexible so that it can be 
used to evaluate the cost- effectiveness of any other intervention 
to prevent LOI during a NICU stay, informing various policy 
decisions, that is, whether new interventions should be adopted 
and how much to invest in future research.
Limitations
The causal effect of LOI on death and hospital costs could not be 
estimated given the small number of deaths. Consequently, the 
model base- case assumes that infants incur the same costs irre-
spective of LOI or survival status, and that LOI does not increase 
the risk of death at 6 months. These assumptions were tested in a 
scenario analysis, and in the comparison between AM- PICC and 
S- PICC, they had no impact on the results. If LOI is linked with 
higher costs and higher risk of death during the NICU stay, its 
prevention can be linked to greater health and economic benefit 
than those estimated above.
The model assumes that LOI increases the risk of death 
and NDI at 2 years of age, based on publications identified 
from a non- systematic citation search. Despite the nature of 
the searches, three systematic reviews were identified2023 and 
screened, providing reassurance that all relevant primary studies 
were identified. The limitation is that the association between 
LOI and NDI/death may not be causal, given the observational 
nature of the data. The impact of varying the effect of LOI 
on cost- effectiveness results was small, but this is likely to be 
related to the limited difference between AM- PICC and S- PICC 
in preventing LOI. Future cost- effectiveness analyses of other 
interventions to prevent LOI should conduct sensitivity analyses 
for these parameters.
The model structure constrains the impact of preventing LOI 
to reducing the risk of NDI and death at 2 years of age. Some 
studies suggest that the impact of LOI on NDI is mediated via 
necrotising enterocolitis.57*LYHQWKDWQRVWXGLHVZHUHLGHQWLILHG
that disentangled the direct effect of LOI on NDI from the indi-
rect effect via antibiotic treatment, necrotising enterocolitis was 
not modelled explicitly.
This study takes the perspective of the NHS for costs and bene-
fits following the National Institute for Health and Care Excel-
lence guidance to evaluate interventions funded by the NHS.11 
This covers hospital costs and costs of community healthcare. It 
was not possible to include the latter over the time period from 
PICC insertion to 2 years of age due to a lack of comprehen-
sive routine healthcare databases which compile such data. Costs 
falling on other sectors, such as social care and education, are 
likely to be relevant, but fall outside the NHS perspective. The 
study considers the impact of LOI on the infants length and 
health- related quality of life only. Health outcomes experienced 
by infants and children may have spill over effects to their family 
and carers,38 39 which were not accounted for here.
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